HOLX · Hologic Inc - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · HOLX

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$4.10B	$4.03B	$4.03B	$4.86B	$5.63B	$3.78B
Cost of Revenue	$1.55B	-	-	-	-	-
Gross Profit	$2.12B	$2.23B	$2.07B	$3.00B	$3.80B	$2.23B
R&D	$248.20M	$272.80M	$294.30M	$283.40M	$276.30M	$222.50M
SG&A	$449.30M	$409.40M	$392.40M	$407.70M	$433.20M	$356.00M
Total Operating Expenses	$1.40B	$1.35B	$1.40B	$1.36B	$1.32B	$1.12B
D&A	$108.90M	$99.30M	$89.60M	$89.20M	$88.00M	$83.10M
Operating Income	$714.30M	$882.60M	$668.40M	$1.64B	$2.48B	$1.10B
Interest Expense	$111.10M	$122.10M	$111.10M	$95.10M	$93.60M	$116.50M
Income Tax	$115.50M	$75.60M	$220.10M	$286.20M	$491.40M	($108.60M)
Net Income	$565.70M	$789.50M	$456.00M	$1.30B	$1.87B	$1.12B
EPS - Basic	$2.50	$3.35	$1.85	$5.18	$7.28	$4.24
EPS - Diluted	$2.49	$3.32	$1.83	$5.13	$7.21	$4.21

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$1.96B	$2.16B	$2.72B	$2.34B	$1.17B	$701.00M
Accounts Receivable	$600.80M	$600.40M	$625.60M	$617.60M	$942.70M	$1.03B
Inventory	$679.40M	$679.80M	$617.60M	$623.70M	$501.20M	$395.10M
Accounts Payable	$193.40M	$203.80M	$175.20M	$197.70M	$215.90M	$178.80M
Current Assets	$3.67B	$3.82B	$4.18B	$3.86B	$3.17B	$2.22B
Total Assets	$9.01B	$9.16B	$9.14B	$9.07B	$8.92B	$7.20B
Current Liabilities	$977.20M	$1.04B	$1.21B	$937.70M	$1.33B	$1.24B
Long-term Debt	$2.50B	$2.50B	$2.53B	$2.81B	$2.71B	$2.71B
Total Liabilities	-	-	-	-	-	-
Stockholders' Equity	$5.05B	$5.13B	$5.02B	$4.88B	$4.22B	$2.71B
Retained Earnings	$3.41B	$2.85B	$2.06B	$1.60B	$298.30M	($1.57B)

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$1.06B	$1.29B	$1.05B	$2.13B	$2.33B	$896.60M
Investing Cash Flow	($482.70M)	($781.00M)	($152.10M)	($206.30M)	($1.33B)	($141.60M)
Financing Cash Flow	($777.20M)	($1.11B)	($483.20M)	($756.00M)	($529.80M)	($659.90M)
CapEx	$58.80M	$72.40M	$91.80M	$70.60M	$96.80M	$98.30M
Free Cash Flow	$998.30M	$1.21B	$959.40M	$2.06B	$2.23B	$798.30M

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	51.6%	55.3%	51.4%	61.6%	67.4%	59.0%
Operating margin	17.4%	21.9%	16.6%	33.7%	44.0%	29.3%
EBITDA margin	20.1%	24.4%	18.8%	35.6%	45.6%	31.5%
Net margin	13.8%	19.6%	11.3%	26.8%	33.2%	29.5%
Free cash flow margin	24.3%	30.1%	23.8%	42.3%	39.7%	21.1%
FCF / Net income	1.76	1.54	2.10	1.58	1.19	0.72
R&D / Revenue	6.1%	6.8%	7.3%	5.8%	4.9%	5.9%
SG&A / Revenue	11.0%	10.2%	9.7%	8.4%	7.7%	9.4%
Effective tax rate	17.0%	8.7%	32.6%	18.0%	20.8%	-10.8%
Return on assets	6.3%	8.6%	5.0%	14.4%	21.0%	15.5%
Return on equity	11.2%	15.4%	9.1%	26.7%	44.4%	41.2%
Return on invested capital	7.9%	10.6%	6.0%	17.5%	28.3%	20.4%
Liquidity
Current ratio	3.75	3.69	3.47	4.12	2.39	1.79
Quick ratio	3.06	3.03	2.95	3.45	2.01	1.47
Cash ratio	2.01	2.08	2.26	2.49	0.88	0.57
Leverage
Debt / Equity	0.50	0.49	0.50	0.58	0.64	1.00
Debt / Assets	0.28	0.27	0.28	0.31	0.30	0.38
Debt / EBITDA	3.04	2.54	3.34	1.62	1.06	2.28
Interest coverage	6.4x	7.2x	6.0x	17.2x	26.5x	9.5x
Equity multiplier	1.79	1.78	1.82	1.86	2.11	2.66
Liabilities / Assets	-	-	-	-	-	-
Efficiency
Asset turnover	0.45	0.44	0.44	0.54	0.63	0.52
Inventory turnover	2.28	-	-	-	-	-
Days sales outstanding	53d	54d	57d	46d	61d	99d
Days inventory outstanding	160d	-	-	-	-	-
Days payable outstanding	46d	-	-	-	-	-
Cash conversion cycle	168d	-	-	-	-	-
Valuation
P / E	27.1x	24.5x	37.9x	12.6x	10.6x	15.3x
P / B	3.0x	3.8x	3.4x	3.4x	4.7x	6.3x
P / S	3.7x	4.8x	4.3x	3.4x	3.5x	4.5x
EV / EBITDA	19.3x	20.1x	22.5x	9.7x	8.3x	16.0x
Growth
Revenue growth (YoY)	1.7%	-0.0%	-17.1%	-13.7%	49.1%	12.1%
Revenue CAGR (3y)	-5.5%	-10.6%	2.2%	13.0%	20.5%	7.3%
Revenue CAGR (5y)	1.7%	3.7%	4.6%	9.7%	14.7%	6.9%
Gross profit growth (YoY)	-4.9%	7.5%	-30.9%	-21.0%	70.4%	90.2%
Operating income growth (YoY)	-19.1%	32.0%	-59.2%	-33.9%	124.5%	-
Net income growth (YoY)	-28.3%	73.1%	-65.0%	-30.4%	67.8%	-
EPS growth (YoY)	-25.0%	81.4%	-64.3%	-28.8%	71.3%	-
EPS CAGR (3y)	-21.4%	-22.8%	-24.2%	-	-	16.8%
EPS CAGR (5y)	-10.0%	-	-	14.2%	44.1%	56.4%
FCF growth (YoY)	-17.7%	26.4%	-53.3%	-8.0%	179.8%	34.7%
FCF CAGR (5y)	4.6%	15.4%	7.3%	-	24.7%	-0.9%
Book value growth (YoY)	-1.6%	2.3%	2.9%	15.6%	55.9%	27.9%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-09-27.

Business segments

$4.10B total

Diagnostics$1.83B · 44.6%

Breast Health$1.48B · 36.2%

Gyn Surgical$679.80M · 16.6%

Skeletal Health$109.40M · 2.7%

Product / service

$6.60B total

Disposables$2.62B · 39.7%

Molecular Diagnostics$1.03B · 15.6%

Breast Imaging$860.20M · 13.0%

Service$825.50M · 12.5%

Capital Equipment Componentsand Software$638.40M · 9.7%

Cytology Perinatal$296.10M · 4.5%

Interventional Breast Solutions$282.10M · 4.3%

Blood Screening$28.20M · 0.4%

Other Typeof Revenue$18.90M · 0.3%

Geographic

$2.88B total

US$1.35B · 47.0%

Europe$591.00M · 20.5%

International$474.50M · 16.5%

Asia Pacific$243.30M · 8.4%

Other Geographic Regions$218.30M · 7.6%

Stability scores

Piotroski F-score

FY 2025 · 9-point quality

6/9

Neutral

✓Net income positive
✓Operating cash flow positive
✗ROA improved YoY
✓Cash flow > net income
✗Long-term debt decreased
✓Current ratio improved
✓No share dilution
✗Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: X-Ray Apparatus & Tubes & Related Irradiation Apparatus

Company	Revenue (last FY)	Net margin	ROE
GEHC	$20.63B	10.1%	20.1%
BFLY	$97.61M	-79.0%	-39.3%
GPFT	$589.0K	-934.6%	94.8%
NNOX	$13.02M	-576.1%	-53.7%

Comparing HOLOGIC INC against the 4 most active filers in the same SIC group.